Showing results (11-20 of 308) with videos related to
Sort By:
Pageof 31
Thrombosis and Haemostasis|March 9, 2011
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verifiedV L SerebruanyAmerican Heart Journal|December 21, 2010
Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?Victor L SerebruanyInternational Journal of Cardiology|August 31, 2015
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target eventsVictor L SerebruanyThrombosis and Haemostasis|October 17, 2012
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrelVictor L SerebruanyCardiovascular Revascularization Medicine : Including Molecular Interventions|March 23, 2011
Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlookVictor L SerebruanyCardiology|December 7, 2011
Extreme all-cause mortality in JUPITER requires reexamination of vital recordsVictor L SerebruanyCardiology|March 16, 2012
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consentVictor L SerebruanyThrombosis and Haemostasis|December 22, 2009
The TRITON versus PLATO trials: differences beyond platelet inhibitionV L SerebruanyInternational Journal of Cardiology|January 25, 2014
Discrepancies in the primary PLATO trial publication and the FDA reviewsVictor L SerebruanyPageof 31